(2R,3R,5S)-2-(6-amino-7,8-dihydropurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3R,5S)-2-(6-amino-7,8-dihydropurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
• 化学式: C₁₀H₁₅N₅O₃
• 分子量: 253.26
• InChiKey: HXJVECTWDNYTOR-BAJZRUMYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• [EN] THERAPEUTIC AGENTS AND CONJUGATES THEREOF<br/>[FR] AGENTS THÉRAPEUTIQUES ET LEUR CONJUGUÉS
  申请人：BEIJING XUANYI PHARMASCIENCES CO LTD

  公开号：WO2021178818A2

  公开（公告）日：2021-09-10

  The present disclosure provides a class of conjugates of general formula (X), a class of TLR9 agonist derivatives, such as formula (I), (XX), and (XXI), certain diastereomers of STING agonists, a class of STING agonist derivatives, such as formula (XXVIV), a class of heterocyclic compounds of general formula (II), a class of heterocyclic compounds of general formula (III), as defined herein. A1, A2, T, Z1, Z2, Z3, b1, and b2, in formula (X) are defined herein. The conjugate provides unique properties that are based upon the properties of the therapeutic agents that are part of the conjugate. Also provided are methods of synthesis and use of compounds.